FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> H1N1 | microneedle

Microneedles may be better for H1N1 delivery

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!


Researchers from Emory and Georgia Tech have found that H1N1 vaccines delivered via microneedles offer better protection than traditional vaccines. The findings were published online in the Journal of Infectious Diseases.

The researchers administered the H1N1 vaccine to mice using either a microneedle patch or a subcutaneous injection. Both test groups were equally protected at the six-week mark, but the mice that got the microneedle patch still had a high level of antibody protection compared to the standard group. They believe this proves that the skin, rather than the muscle, offers a more efficient way to develop effective vaccines.

"Our research shows that skin-based vaccination, made possible through microneedle technology, may now be a viable and more effective alternative to intramuscular injection for H1N1 flu and other strains as well," lead researcher Ioanna Skountzou. Another researcher on the project, Georgia Tech bioengineer Mark Prausnitz, adds that microneedles offer logistical advantages because they're easier to manufacture, smaller to ship and simpler to administer.

- read the report for more

Special Report: Microneedles - Game-Changing Drug Delivery Technologies

Related Articles:
FDA okays Sanofi's microinjection flu vaccine‎
FluGen lands $7.8M for microneedle vaccine delivery patch

Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:

More stories about H1N1   microneedle